Here are five things to know:
1. Anika’s first quarter 2016 net income was 45 cents a share, up 96 percent from 23 cents a year ago and beating out analyst views which polled at 28 cents.
2. Total revenue for the quarter grew 44 percent to $22.3 million, which also beat analyst views, predicted at $19.3 million.
3. Anika’s injectable therapies are known as hyaluronic acid viscosupplementation products, which are designed to not only ease varying stages of pain, but also stave off expensive knee surgeries or replacements.
4. Charles Sherwood, CEO of Anika Therapeutics, said the worldwide market for hyaluronic treatments is roughly $2 billion and is growing 5 percent to 8 percent per year.
5. The American Medical Society for Sports Medicine has recommended the use of hyaluronic treatments for appropriate patients with knee osteoarthritis.
More articles on devices and implants:
Zimmer Biomet, NuVasive, Wenzel Spine & more: 21 key notes
Stryker to launch Tritanium Posterior Lumbar Cage: 4 takeaways
Analysts rate K2M shares: 5 facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
